Related Experiment Video

Updated: Aug 7, 2026

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Neurohormones and heart failure: the importance of aldosterone

K Odedra1, A Ferro

  • 1Faculty of Medicine and Cardiovascular Division, GKT School of Medicine, King's College London, London, UK.

International Journal of Clinical Practice
|July 19, 2006
PubMed

Insights

Aldosterone contributes to heart failure progression through direct effects on the heart and blood vessels. Mineralocorticoid receptor antagonists show promise in treating heart failure by improving patient outcomes.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Heart failure is a growing cause of cardiovascular disease, with increasing incidence.
  • Aldosterone plays a significant role in heart failure pathophysiology.
  • Emerging evidence highlights aldosterone's renal-independent effects.

Purpose of the Study:

  • To review the role of aldosterone in heart failure.
  • To discuss the direct effects of aldosterone on the myocardium and vasculature.
  • To highlight mineralocorticoid receptor antagonists as a treatment paradigm.

Main Methods:

  • Review of recent scientific literature and clinical trials.
  • Analysis of aldosterone's binding to mineralocorticoid receptors.
  • Examination of aldosterone's impact on cardiac and vascular tissues.

Main Results:

  • Aldosterone directly causes myocardial hypertrophy, necrosis, and fibrosis.
  • Aldosterone contributes to endothelial dysfunction.
  • Mineralocorticoid receptor antagonists have demonstrated benefits in reducing morbidity and mortality.

Conclusions:

  • Aldosterone has direct detrimental effects on the heart and vasculature, independent of renal function.
  • Mineralocorticoid receptor antagonists represent a significant advancement in heart failure treatment.
  • Further research supports the use of these agents in managing chronic symptomatic heart failure.

More Related Videos

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System06:40

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Hormonal Regulation01:33

Hormonal Regulation

The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...